Detalhe da pesquisa
1.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Nature
; 603(7903): 942-948, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35322232
2.
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
N Engl J Med
; 386(5): 449-462, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108470
3.
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 401(10389): 1655-1668, 2023 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068504
4.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Oncologist
; 29(4): e514-e525, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38297981
5.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
N Engl J Med
; 384(13): 1191-1203, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789008
6.
State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.
Curr Opin Oncol
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38726797
7.
Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
J Natl Compr Canc Netw
; 22(3)2024 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38503041
8.
Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment.
Gut
; 72(4): 624-637, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36002248
9.
Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.
Gut
; 72(9): 1651-1663, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36918265
10.
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
Lancet Oncol
; 24(7): 744-756, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37329891
11.
Clinically conserved genomic subtypes of gastric adenocarcinoma.
Mol Cancer
; 22(1): 147, 2023 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37674200
12.
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
Oncologist
; 28(6): 553-e472, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36940261
13.
Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy.
Ann Surg Oncol
; 30(8): 4936-4945, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37106276
14.
Localized Gastroesophageal Adenocarcinoma in the Elderly: Is Age a Factor Associated with Suboptimal Treatment?
Oncology
; 101(3): 153-158, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36412619
15.
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(4): 393-422, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37015332
16.
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.
Future Oncol
; 19(11): 739-752, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36919706
17.
Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment.
Chin J Cancer Res
; 35(1): 44-57, 2023 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36910854
18.
Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency.
Gut
; 71(3): 467-478, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785559
19.
Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-analysis.
Ann Surg
; 275(3): 467-476, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34191461
20.
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet
; 398(10294): 27-40, 2021 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34102137